Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Christian Koenecke, MD, Philipp Kümpers, MD, Alexander Lukasz, Hartmut Hecker, MD, Elke Dammann, Willem Verhagen, MD, Sascha David, MD, Gudrun Göhring, MD, Stefanie Buchholz, MD, Eva Weissinger, MD, PhD, Jürgen Krauter, MD, Ph.D., Matthias Eder, MD, Ph.D., Hermann Haller, MD, Ph.D., Arnold Ganser, MD, PhD

Blood (2008) 112 (11): 3259.

https://doi.org/10.1182/blood.V112.11.3259.3259

Published: 2008

Journal Articles

Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies

Philipp Kümpers, Christian Koenecke, Hartmut Hecker, Julian Hellpap, Rüdiger Horn, Willem Verhagen, Stefanie Buchholz, Bernd Hertenstein, Jürgen Krauter, Matthias Eder, Sascha David, Gudrun Göhring, Hermann Haller, Arnold Ganser

Blood (2008) 112 (5): 2139–2148.

https://doi.org/10.1182/blood-2007-12-130021

Published: 2008

Journal Articles

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Guntram Buesche, Rudiger Hehlmann, Arnold Ganser, Hartmut Hecker, Andreas Hochhaus, Hermann Heimpel, Barbara Heinze, Claudia Schoch, PD., Dorothea Gadzicki, Martin Mueller, Nils von Neuhoff, Susanne Schnittger, PD., Brigitte Schlegelberger, Bernd Frye, Axel Georgii, Hans Kreipe

Blood (2006) 108 (11): 2195.

https://doi.org/10.1182/blood.V108.11.2195.2195

Published: 2006

Journal Articles

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Guntram Buesche, Ruediger Hehlmann, Arnold Ganser, Hartmut Hecker, Mathias Freund, Hermann Heimpel, Barbara Heinze, Dorothea Gadzicki, Brigitte Schlegelberger, Christa Fonatsch, Bernd Frye, Andreas Tobler, Axel Georgii, Hans H. Kreipe

Blood (2005) 106 (11): 1106.

https://doi.org/10.1182/blood.V106.11.1106.1106

Published: 2005

Journal Articles

Marrow Fibrosis in Myelodysplastic Syndromes - Its Significance in the Context of the WHO Classification of Disease and the International Prognostic Scoring System.

Guntram Buesche, Arnold Ganser, Ludwig Wilkens, PD., Brigitte Schlegelberger, Hartmut Hecker, Axel Georgii, Hans H. Kreipe

Blood (2004) 104 (11): 1446.

https://doi.org/10.1182/blood.V104.11.1446.1446

Published: 2004

NARROW

Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Marrow Fibrosis in Myelodysplastic Syndromes - Its Significance in the Context of the WHO Classification of Disease and the International Prognostic Scoring System.

Email alerts

ASH Publications

American Society of Hematology

Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Marrow Fibrosis in Myelodysplastic Syndromes - Its Significance in the Context of the WHO Classification of Disease and the International Prognostic Scoring System.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only